{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:13:34Z","timestamp":1791112414067,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,10]]},"DOI":"10.1097\/01.aids.0000171405.46113.bf","type":"journal-article","created":{"date-parts":[[2005,5,19]],"date-time":"2005-05-19T04:03:04Z","timestamp":1116475384000},"page":"917-925","source":"Crossref","is-referenced-by-count":82,"title":["Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine"],"prefix":"10.1097","volume":"19","author":[{"given":"Cesar","family":"Fisac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Fumero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Roson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Virgili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"issue":"Suppl 2","key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1086\/367562","article-title":"Lipid abnormalities","volume":"36","author":"Dube","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1086\/367564","article-title":"Insulin and carbohydrate dysregulation","volume":"36","author":"Gelato","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1210\/jc.2002-020794","article-title":"Lipodystrophy in human immunodeficiency virus-infected patients","volume":"87","author":"Chen","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"48S","DOI":"10.1016\/S0002-9343(98)00212-5","article-title":"Epidemiologic aspects of lipid abnormalities","volume":"105","author":"Criqui","year":"1998","journal-title":"Am J Med"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00041433-199608000-00008","article-title":"Insulin resistance and coronary heart disease","volume":"7","author":"Laakso","year":"1996","journal-title":"Curr Opin Lipidol"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00002018-200124030-00001","article-title":"Lipodystrophy syndrome in patients with HIV infection: quality of life issues","volume":"24","author":"Martinez","year":"2001","journal-title":"Drug Saf"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/343050","article-title":"Switching effective antiretroviral therapy","volume":"35","author":"Drechsler","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R9-8-20210130","first-page":"233","article-title":"Simplification of antiretroviral treatment: how to sustain success, reduce toxicity and ensure adherence avoiding PI use","volume":"4","author":"Barreiro","year":"2002","journal-title":"AIDS Rev"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"R11-8-20210130","article-title":"Anthropometric Standardization Reference Manual","author":"Lohman","year":"1988"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1 ingected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1520-037X.2002.00980.x","article-title":"Perspectives: the significance of measuring non-HDL-cholesterol","volume":"5","author":"Hirsch","year":"2002","journal-title":"Prev Cardiol"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/oby.2004.118","article-title":"Resistin, adiponectin, ghrelin, leptin and proinflammatory citokines: relationships in obesity","volume":"12","author":"Vendrell","year":"2004","journal-title":"Obes Res"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R17-8-20210130","first-page":"413","article-title":"Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir","volume":"6","author":"Walli","year":"2001","journal-title":"Eur J Med Res"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1310\/EJRF-JGGH-GRCD-MED8","article-title":"Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to trizivir versus continued HAART: the Trizal Study","volume":"4","author":"Lafeuillade","year":"2003","journal-title":"HIV Clin Trials"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/340312","article-title":"A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection","volume":"185","author":"Opravil","year":"2002","journal-title":"J Infect Dis"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00002030-200108170-00009","article-title":"Simplification with abacavir-based tripled nucleoside therapy versus continued protease-inhibitor based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1-RNA","volume":"15","author":"Clumeck","year":"2001","journal-title":"AIDS"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00126334-200305010-00004","article-title":"A 48-week, randomised, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipodystrophy","volume":"33","author":"Moyle","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","article-title":"Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine","volume":"16","author":"Negredo","year":"2002","journal-title":"AIDS"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1310\/X9BK-C45Q-HQKJ-WJ4N","article-title":"Switch to efavirenz in a protease inhibitor-containing regimen","volume":"2","author":"Knechten","year":"2001","journal-title":"HIV Clin Trials"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-121-9-199411010-00002","article-title":"Cholesterol and coronary heart disease: predicting risks by levels and ratios","volume":"121","author":"Kinosian","year":"1994","journal-title":"Ann Intern Med"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.285.19.2481","article-title":"Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral artery disease","volume":"285","author":"Ridker","year":"2001","journal-title":"JAMA"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1086\/339866","article-title":"Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy","volume":"34","author":"Sav\u00e8s","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-199905070-00009","article-title":"Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine","volume":"13","author":"Martinez","year":"1999","journal-title":"AIDS"},{"key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/317426","article-title":"Impact of switching from human immunodeficiency virus type I protease inhibitors to efavirenz in successfully treated adults with lipodystrophy","volume":"31","author":"Martinez","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R31-8-20210130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00126334-200112010-00016","article-title":"Changes in metabolic parameters and body shape after replacement of protease inhibitors with efavirenz in virologically controlled HIV-1-positive persons: single arm observational cohort","volume":"28","author":"Moyle","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl.1","key":"R32-8-20210130","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.2337\/diabetes.53.2007.S143","article-title":"Update on adipocyte hormones","volume":"53","author":"Havel","year":"2004","journal-title":"Diabetes"},{"key":"R33-8-20210130","first-page":"621","article-title":"Potential role of TNF-\u03b1 in the pathogenesis of insulin resistance and type 2 diabetes","volume":"245","author":"Moller","year":"1999","journal-title":"Trends Endocrinol Metab"},{"key":"R34-8-20210130","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/jc.2002-020795","article-title":"Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy","volume":"88","author":"Addy","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-8-20210130","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1210\/jc.2002-021600","article-title":"Regulation of adiponectin in human-immunodeficiency virus-infected patients: relationship to body composition and metabolic indices","volume":"88","author":"Tong","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-8-20210130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00126334-200012010-00004","article-title":"Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy","volume":"25","author":"Mynarcik","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R37-8-20210130","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200109280-00010","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"R38-8-20210130","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2337\/diacare.25.7.1177","article-title":"Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease","volume":"25","author":"Hanley","year":"2002","journal-title":"Diabetes Care"},{"key":"R39-8-20210130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/07853899608999104","article-title":"Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease","volume":"28","author":"Yudkin","year":"1996","journal-title":"Ann Med"},{"key":"R40-8-20210130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R41-8-20210130","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogues therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"R42-8-20210130","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"R43-8-20210130","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"R44-8-20210130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.aids.0000171405.46113.bf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:31:58Z","timestamp":1785853918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200506100-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,10]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.aids.0000171405.46113.bf","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6,10]]}}}